Brazil Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
Brazil active pharmaceutical ingredient cdmo market, 2018-2030 (US$M)
Related Markets
Brazil active pharmaceutical ingredient cdmo market highlights
- The Brazil active pharmaceutical ingredient cdmo market generated a revenue of USD 3,862.1 million in 2023 and is expected to reach USD 6,446.9 million by 2030.
- The Brazil market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2023.
- Antibody Drug Conjugate (ADC is the most lucrative product segment registering the fastest growth during the forecast period.
Active pharmaceutical ingredient cdmo market data book summary
| Market revenue in 2023 | USD 3,862.1 million |
| Market revenue in 2030 | USD 6,446.9 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, Brazil accounted for 3.3% of the global active pharmaceutical ingredient cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil active pharmaceutical ingredient cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 6,446.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil active pharmaceutical ingredient cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.62% in 2023. Horizon Databook has segmented the Brazil active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil accounted for 40.7% of Latin America’s market in 2020. Supportive government initiatives aimed at increasing investments in pharmaceutical & biotechnology industry by substituting imports with domestic products and encouraging partnerships between foreign & local companies are expected to increase the number of multinational pharmaceutical & biotechnology companies in Brazil.
Brazil’s National Health Surveillance Agency recently added a regulatory requirement that manufacturing services companies must attain a license as a medical manufacturing unit to maintain quality, safety, and performance parameters. This has made Brazil a lucrative market for various foreign manufacturers.
Growing number of clinical trials in the country is projected to create opportunities for the active pharmaceutical ingredient CDMOs. According to WHO ICTRP, 16,550 clinical trials were conducted in Brazil between 1999 and 2020.
Reasons to subscribe to Brazil active pharmaceutical ingredient cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Brazil active pharmaceutical ingredient cdmo market databook
-
Our clientele includes a mix of active pharmaceutical ingredient cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Brazil active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Brazil active pharmaceutical ingredient cdmo market size, by product, 2018-2030 (US$M)
Brazil Active Pharmaceutical Ingredient CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
